Loading
institutionsInstitution
Guangdong Provincial People's Hospital
Home of the Guangdong Lung Cancer Institute, where Yi-Long Wu's group ran the trials that made EGFR-mutant lung cancer a targeted-therapy disease in Asia.
Also called: GDPHGuangdong Lung Cancer InstituteGuangdong Academy of Medical Sciences广东省人民医院
Overview
Guangdong Provincial People's Hospital, founded in 1946, houses the Guangdong Lung Cancer Institute led by Yi-Long Wu, one of the most influential lung cancer trial groups in the world. Its investigators led or co-led OPTIMAL (erlotinib), CTONG 1104/ADJUVANT (adjuvant gefitinib), the Chinese arms of ADAURA and FLAURA, and studies of neoadjuvant immunotherapy in NSCLC, and founded the Chinese Thoracic Oncology Group (CTONG). Beyond lung cancer the hospital is strong in cardiology, cardiothoracic surgery and precision pathology, and runs a large next-generation sequencing service for lung cancer.
Location
Guangzhou, CN
Type
hospital · Southern Medical University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#157 · 32 points (0 Newsweek + 0 NCI + 32 from 16 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Guangdong Provincial People's Hospital, including child institutions. 769 works · 8,924 citations · 75% open access · 12% clinical trials · 2% reviews.
Oncology works per year
1572022
1682023
1562024
1632025
1252026
Most works
- Yi-Long Wu81 works
- Wen‐Zhao Zhong33 works
- Qing Zhou31 works
- Zaiyi Liu31 works
- Kun Wang20 works
- Xueqing Yao19 works
- Chong‐Rui Xu19 works
- Zhenhui Li18 works
- Hai‐Yan Tu16 works
- Junjiang Wang15 works
Most cited
- Guangdong Lung Cancer Institute
- EGFR-mutant NSCLC trials (CTONG)
- Neoadjuvant immunotherapy
- Molecular pathology
Nu Zhang
President (Yuanzhang) and Deputy Party Secretary
Hospital leadership
President of Guangdong Provincial People's Hospital in Guangzhou, one of China's largest tertiary hospitals and home to the Guangdong Lung Cancer Institute.
Qing Zhou
Chief of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
EGFR-mutant lung cancerBispecific antibodiesImmunotherapy
Chinese thoracic oncologist behind HARMONi-2, where the PD-1/VEGF bispecific ivonescimab beat pembrolizumab head to head.
Wen-Zhao Zhong
Vice President and Party Standing Committee Member
Thoracic surgeryLung cancerEGFR-mutant NSCLC
Thoracic surgeon-scientist and hospital Vice President who led the ADJUVANT/CTONG1104 trial establishing adjuvant EGFR-TKI therapy in resected lung cancer.
Yi-Long Wu
Professor; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
Lung cancerEGFR-mutant NSCLCAdjuvant targeted therapy
Co-led ADAURA and IPASS, the trials that made EGFR-targeted pills standard before and after surgery.
Similar pages
- Key paperADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer
Shares Yi-Long Wu, ADAURA, Oncogene addiction, Osimertinib.
- Key paperADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer
Shares Yi-Long Wu, ADAURA, Osimertinib, Neoadjuvant / adjuvant / perioperative.
- InstitutionShanghai Pulmonary Hospital
Shares ALK, EGFR, PD-1, Small-molecule kinase inhibitors.
- TrialALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
Shares Erlotinib, Osimertinib, Neoadjuvant / adjuvant / perioperative, Comprehensive genomic profiling.
- Key paperDacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Shares Yi-Long Wu, Gefitinib, EGFR, Non-small-cell lung cancer.
- Key paperImprovement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations
Shares Yi-Long Wu, Gefitinib, EGFR, Non-small-cell lung cancer.
- TrialFURLONG
Shares FLAURA2, Gefitinib, EGFR, Small-molecule kinase inhibitors.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares ALK, Osimertinib, EGFR, Small-molecule kinase inhibitors.
cancers
fronts
technologies
targets
drugs
ApprovedSmall-molecule EGFR TKI (first generation, reversible)
Erlotinib · Tarceva
ApprovedSmall-molecule EGFR TKI (first generation, reversible)
Gefitinib · Iressa
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso